
Instil Bio (TIL) Stock Forecast & Price Target
Instil Bio (TIL) Analyst Ratings
Bulls say
Instil Bio, Inc. is poised for a positive outlook due to its innovative cell therapy pipeline focused on autologous tumor infiltrating lymphocyte therapies and its development of genetically engineered TIL therapies through the CoStAR platform. The key asset, ITIL-306, addresses a wide range of solid tumors, including ovarian and renal cancers, positioning the company to tap into substantial market opportunities as treatment options expand. Additionally, the broader success of related therapies, as evidenced by encouraging data from studies such as HARMONi, may create a supportive environment for Instil Bio's advancements and encourage investor confidence in the potential for growth.
Bears say
Instil Bio Inc faces significant investor skepticism, particularly due to the perceived underwhelming shift in overall survival (OS) curves reported in recent updates, which has led bearish investors to focus on this aspect. The company is also confronted with multiple risks, including potential delays in clinical assessments and the possibility of failing to produce positive clinical data, notably for its candidate, AXN-2510, in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Additionally, there are concerns regarding medium- to long-term dilution risks, further contributing to a negative outlook on the stock’s future performance.
This aggregate rating is based on analysts' research of Instil Bio and is not a guaranteed prediction by Public.com or investment advice.
Instil Bio (TIL) Analyst Forecast & Price Prediction
Start investing in Instil Bio (TIL)
Order type
Buy in
Order amount
Est. shares
0 shares